Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Oncogene. 2015 Mar 16;34(48):5912–5922. doi: 10.1038/onc.2015.41

Figure 5.

Figure 5

C/EBPβ is required for high expression levels of cell cycle inhibitors upon AR inhibition. (a) Total cellular proteins extracted from parental (P) LNCaP cells or individual clones transfected with TALEN-C/EBPβ were subjected to Western blotting using C/EBPβ or actin antibodies. (b) LNCaP cells harboring an inducible shRNA against C/EBPβ (shC/EBPβ) or non-targeting vector (NTV) were cultured with doxycycline (200 ng/ml) for 48 hrs and protein extracts were subjected to immunoblotting with the indicated antibodies. (c) LNCaP cells harboring shCEBPB or non-targeting vector (shNTV) cultured with doxycycline (200 ng/ml) in androgen replete (ARM) or androgen depleted media (ADM) for 7 days, were stained with propidium iodide and DNA content was analyzed by flow cytometry. Mean distribution of cells in G1, S, or G2/M from three experiments. (d) LNCaP cells expressing shNTV or shCEBPB were cultured in ARM or ADM for 7 days and the expression of the indicated cell cycle regulators was assessed by Western blotting.